Provencio, MarianoCobo, ManuelRodriguez-Abreu, DelvysCalvo, VirginiaCarcereny, EnricCantero, AlexandraBernabe, ReyesBenitez, GretelCastro, Rafael LópezMassuti, BartomeuDel Barco, EdelGarcía Campelo, RosarioGuirado, MariaCamps, CarlosOrtega, Ana LauraGonzalez-Larriba, Jose LuisSanchez, AlfredoCasal, JoaquínSala, M AngelesJuan-Vidal, OscarBosch-Barrera, JoaquimOramas, JuanaDomine, ManuelTrigo, Jose ManuelBlanco, RemeiCalzas, JuliaMorilla, IdoiaPadilla, AiramPimentao, JoaoSousa, Pedro ATorrente, Maria2023-05-032023-05-032022-06-27Provencio M, Cobo M, Rodriguez-Abreu D, Calvo V, Carcereny E, Cantero A, et al. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics. BMC Cancer. 2022 Jul 5;22(1):732http://hdl.handle.net/10668/20282The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself. This work aims to study the situation of biomarker testing in Spain. The Thoracic Tumours Registry (TTR) is an observational, prospective, registry-based study that included patients diagnosed with lung cancer and other thoracic tumours, from September 2016 to 2020. This TTR study was sponsored by the Spanish Lung Cancer Group (GECP) Foundation, an independent, scientific, multidisciplinary oncology society that coordinates more than 550 experts and 182 hospitals across the Spanish territory. Nine thousand two hundred thirty-nine patients diagnosed with stage IV non-small cell lung cancer (NSCLC) between 2106 and 2020 were analysed. 7,467 (80.8%) were non-squamous and 1,772 (19.2%) were squamous. Tumour marker testing was performed in 85.0% of patients with non-squamous tumours vs 56.3% in those with squamous tumours (p-value Despite the lack of a national project and standard protocol in Spain that regulates the determination of biomarkers, the situation is similar to other European countries. Given the growing number of different determinations and their high positivity, national strategies are urgently needed to implement next-generation sequencing (NGS) in an integrated and cost-effective way in lung cancer.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/BiomarkersMetastatic lung cancerTargeted therapiesTestingBiomarkers, TumorCarcinoma, Non-Small-Cell LungDemographyErbB ReceptorsHumansLung NeoplasmsProspective StudiesProtein-Tyrosine KinasesProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesSpainresearch article35790916open accessBiomarkers, TumorCarcinoma, Non-Small-Cell LungDemographyErbB ReceptorsHumansLung NeoplasmsProspective StudiesProtein-Tyrosine Kinases10.1186/s12885-022-09830-81471-2407PMC9254518https://bmccancer.biomedcentral.com/counter/pdf/10.1186/s12885-022-09830-8https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254518/pdf